SCYNEXIS (SCYX)
NASDAQ:SCYX
Want to see SCYX full AI Analyst Report?
Top Page
SCYNEXIS
(NASDAQ:SCYX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.68
▲(3.33% Upside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by weak financial performance (recent large losses and ongoing cash burn) and bearish technicals (downtrend with negative momentum). Offsetting these risks, recent corporate actions—SCY-770 acquisition and the $40M financing extending runway to mid-2029—meaningfully improve strategic positioning and liquidity, but not enough to outweigh current operating weakness.
Positive Factors
Conservative balance sheet
Low debt relative to equity and a conservative capital structure provide durable financial flexibility to fund clinical programs and commercialization over the next 2–6 months. This cushion reduces immediate refinancing risk and supports execution of the SCY-770 development plan while management pursues milestones.
Negative Factors
Negative operating and free cash flow
Operating and free cash flow remain negative on a TTM basis, meaning the company is not yet self-funding. Persistent cash burn increases reliance on external financing to support trials and commercialization, raising execution risk if capital markets tighten or milestone-based financing stalls.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low debt relative to equity and a conservative capital structure provide durable financial flexibility to fund clinical programs and commercialization over the next 2–6 months. This cushion reduces immediate refinancing risk and supports execution of the SCY-770 development plan while management pursues milestones.
Read all positive factors
SCYNEXIS (SCYX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$54.43M
Dividend YieldN/A
Average Volume (3M)612.75K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth673.54%
EPS Growth23.14%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.45
Shares Outstanding79,442,635
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.08
Enterprise Value/Gross Profit-0.08
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$3.50Price Target Upside430.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$1.17M
SCYNEXIS Business Overview & Revenue Model
Company Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its le...
How the Company Makes Money
SCYNEXIS generates revenue primarily from (1) product sales of its approved antifungal, Brexafemme (ibrexafungerp), through commercialization in markets where it or its commercial partners sell the product, and (2) collaboration-related income suc...
SCYNEXIS Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.34M | 20.60M | 3.75M | 140.14M | 5.09M | 13.16M |
| Gross Profit | 20.34M | 20.60M | 3.75M | 124.52M | 4.46M | 12.85M |
| EBITDA | -20.16M | -8.44M | -18.58M | 70.89M | -59.91M | -32.91M |
| Net Income | -24.52M | -8.61M | -21.29M | 67.04M | -62.81M | -32.87M |
Balance Sheet | ||||||
| Total Assets | 77.63M | 59.03M | 90.64M | 128.41M | 87.81M | 119.84M |
| Cash, Cash Equivalents and Short-Term Investments | 59.26M | 21.26M | 59.30M | 74.36M | 73.50M | 104.48M |
| Total Debt | 2.06M | 2.17M | 16.27M | 15.08M | 48.60M | 43.63M |
| Total Liabilities | 36.32M | 9.65M | 35.57M | 55.45M | 84.58M | 78.58M |
| Stockholders Equity | 41.31M | 49.38M | 55.08M | 72.96M | 3.23M | 41.26M |
Cash Flow | ||||||
| Free Cash Flow | -5.92M | -5.28M | -24.01M | 60.16M | -79.89M | -55.73M |
| Operating Cash Flow | -5.92M | -5.28M | -24.01M | 60.16M | -79.88M | -54.56M |
| Investing Cash Flow | 11.34M | 24.31M | 6.15M | -34.88M | -27.39M | -1.17M |
| Financing Cash Flow | 23.95M | -14.17M | -139.00K | -36.72M | 48.60M | 67.12M |
SCYNEXIS Technical Analysis
Negative
0.66
Price Trends
0.92
Negative
0.82
Negative
0.80
Negative
Market Momentum
-0.07
Positive
25.99
Positive
4.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.90, below the 50-day MA of 0.92, and below the 200-day MA of 0.80, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 25.99 is Positive, neither overbought nor oversold. The STOCH value of 4.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCYX.
SCYNEXIS Risk Analysis
SCYNEXIS disclosed 44 risk factors in its most recent earnings report. SCYNEXIS reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SCYNEXIS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $76.71M | -3.87 | -28.75% | ― | 2.08% | -106.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $23.38M | 61.52 | 0.27% | ― | 82.13% | ― | |
49 Neutral | $54.43M | -0.55 | -57.16% | ― | 673.54% | 23.14% | |
49 Neutral | $30.84M | >-0.01 | -4587.82% | ― | -30.75% | -1056.69% | |
47 Neutral | $22.54M | -1.28 | -107.16% | ― | -18.24% | -2264.65% | |
42 Neutral | $1.41M | -0.46 | -93.87% | ― | -6.14% | -24.22% |
* Healthcare Sector Average
SCYX
SCYNEXIS
0.66
-0.14
-17.90%
RMTI
Rockwell Med
0.80
-0.27
-25.42%
TXMD
TherapeuticsMD
2.04
0.55
36.91%
AYTU
Aytu BioScience
2.08
0.05
2.46%
CPIX
Cumberland Pharmaceuticals
5.41
0.38
7.55%
IMCC
IM Cannabis Corp
0.22
-1.50
-87.03%
SCYNEXIS Corporate Events
Executive/Board Changes
SCYNEXIS Director Steven Gilman Announces Board Retirement
Neutral
Apr 20, 2026
On April 16, 2026, SCYNEXIS director Steven C. Gilman notified the company that he will retire from the Board and will not stand for reelection at the 2026 annual meeting of stockholders. His term will end at the conclusion of that meeting, at whi...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
Positive
Mar 31, 2026
On March 31, 2026, SCYNEXIS held a conference call to discuss a strategic asset acquisition and broader corporate update, highlighting its purchase of global rights to SCY-770 from French biotech Poxel. The company detailed that SCY-770 is a well-...
Business Operations and StrategyM&A Transactions
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
Positive
Mar 31, 2026
On March 30, 2026, SCYNEXIS entered an asset purchase agreement to acquire Poxel SA’s direct AMP kinase activator program, including the clinical-stage compound PXL-770, now renamed SCY-770, and all related intellectual property, regulatory ...
Business Operations and StrategyPrivate Placements and Financing
SCYNEXIS Raises $40 Million in Strategic Private Placement
Positive
Mar 31, 2026
On March 30, 2026, SCYNEXIS agreed to raise approximately $40 million in gross proceeds through a private placement of 34.75 million common shares, 8.75 million pre-funded warrants and 43.5 million common warrants to new and existing institutional...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.